Circio Holding ASA

Prospectus • Oct 1, 2025

Circio Holding ASA Approval and publication of prospectus for potential future share issues and conversion of convertible bonds

Circio Holding ASA Approval and publication of prospectus for potential future share issues and conversion of convertible bonds

The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today

approved a securities note, a registration document and a summary (together

referred to as the "Prospectus"), which prepares for potential future share

issues and conversions of bonds under the bond terms and the Investment

Agreement with Atlas Special Opportunities LLC and Atlas Capital Markets LLC.

The Prospectus is available on the Company's

website: https://www.circio.com/en/section/investors/prospectus/

(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.circio.com%2Fen%2Fsection%2Finvestors%2Fprospectus%2F&data=05%7C02%7Cmats.hermansen%40circio.com%7C5b2e58c7684c4d70a6ac08ddfb51ad30%7C66b0661a3ec348a8a9665b0cce82b3fe%7C0%7C0%7C638943050431341713%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=9SJuyOMF64W0LRHXWdxnIB0L95IPhXj3qSImT75gnGo%3D&reserved=0)

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Lubor Gaal, CFO

Phone: +34 683 34 3811

Email: lubor.gaal@circio.com

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 40-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology

program, TG01, through cost-efficient external academic and industry

collaborations. TG01 targets RAS-mutated cancers and is being tested in two

clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine

adjuvanted by STIMULON QS-21 licensed from Agenus Inc.